KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income from Continuing Operations: 2014-2024

Historic Income from Continuing Operations for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$408.0 million.

  • CRISPR Therapeutics AG's Income from Continuing Operations fell 23.82% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$530.0 million, marking a year-over-year decrease of 96.03%. This contributed to the annual value of -$408.0 million for FY2024, which is 121.25% down from last year.
  • CRISPR Therapeutics AG's Income from Continuing Operations amounted to -$408.0 million in FY2024, which was down 121.25% from -$184.4 million recorded in FY2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Income from Continuing Operations peaked at $377.7 million during FY2021, and registered a low of -$652.5 million during FY2022.
  • Its 3-year average for Income from Continuing Operations is -$415.0 million, with a median of -$408.0 million in 2024.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 633.48% in 2020, then surged by 205.94% in 2021.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Income from Continuing Operations stood at -$356.5 million in 2020, then skyrocketed by 205.94% to $377.7 million in 2021, then crashed by 272.78% to -$652.5 million in 2022, then surged by 71.74% to -$184.4 million in 2023, then tumbled by 121.25% to -$408.0 million in 2024.